Last mentioned: Mar 20, 2026
Data Readout
Expected top-line data from Phase 3 adjunctive MDD trials.
Earnings Call
CEO Sergio Traversa provides update on Reliance II and Reliance III trials.
Enrollment Completion
Anticipated completion of enrollment for the pivotal Reliance II study.
Q4 2025 Close
Relmada concludes fiscal year with focus on Phase 3 enrollment.
Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its pivotal trials while maintaining a strategic cash position to reach key clinical milestones.
This page surfaces every story mentioning Relmada Therapeutics, Inc. across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Relmada Therapeutics, Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |